

**Supplementary Table 2.** Patient characteristics according to the grade of hepatic steatosis

|                                      | S0 (n=34)        | S1 (n=41)        | S2 (n=22)        | S3 (n=8)           |
|--------------------------------------|------------------|------------------|------------------|--------------------|
| Age (year)                           | 30.5 (27.0–37.0) | 38.0 (26.8–54.5) | 48.0 (43.0–63.0) | 34.0 (22.0–47.0)   |
| Sex (male:female)                    | 15:19            | 23:18            | 11:11            | 4:4                |
| Body mass index (kg/m <sup>2</sup> ) | 21.8 (20.7–25.1) | 25.2 (23.1–27.2) | 26.4 (24.0–30.7) | 23.6 (22.7–27.0)   |
| Hypertension                         | 4 (11.8)         | 13 (31.7)        | 13 (59.1)        | 1 (12.5)           |
| Diabetes mellitus                    | 0                | 5 (12.2)         | 11 (50.0)        | 4 (50.0)           |
| ALT (IU/L)                           | 10.5 (8.0–18.0)  | 22.0 (14.8–37.0) | 58.5 (40.0–88.0) | 168.0 (30.0–246.5) |
| AST (IU/L)                           | 17.5 (15.0–21.0) | 21.0 (17.0–33.8) | 43.5 (25.0–60.0) | 98.0 (63.5–139.5)  |
| Albumin (mg/dL)                      | 4.2 (4.1–4.4)    | 4.4 (4.1–4.5)    | 4.2 (4.0–4.5)    | 4.2 (3.0–5.0)      |
| Total bilirubin (mg/dL)              | 0.6 (0.4–0.8)    | 0.7 (0.5–1.0)    | 0.6 (0.4–0.6)    | 1.0 (0.3–1.4)      |
| PT-INR                               | 1.03 (0.95–1.09) | 1.01 (0.98–1.07) | 1.00 (0.97–1.01) | 1.07 (1.01–1.16)   |

Values are presented as median (IQR) or number (%).

ALT, alanine aminotransferase; AST, aspartate aminotransferase; PT-INR, prothrombin time international normalized ratio; IQR, interquartile range.

**Supplementary Table 3.** Evaluation of steatosis using attenuation coefficient and controlled attenuation parameters in patients with BMI less than 25 (n=58)

|  | ≥S1 (≥5% steatosis) | ≥S2 (≥34% steatosis) | ≥S3 (≥67% steatosis) |
|--|---------------------|----------------------|----------------------|
| Attenuation coefficient from ATI         |                     |                      |                      |
| AUROC (95% CI)                           | 0.93 (0.83–0.98)    | 0.99 (0.92–1.00)     | 0.99 (0.91–1.00)     |
| Prevalence (n)                           | 33                  | 13                   | 5                    |
| Cutoff (dB/cm/MHz)                       | 0.62                | 0.72                 | 0.83                 |
| Sensitivity                              | 0.82 (27/33)        | 1.00 (13/13)         | 1.00 (5/5)           |
| Specificity                              | 0.96 (24/25)        | 0.93 (42/45)         | 0.96 (51/53)         |
| PPV                                      | 0.96 (27/28)        | 0.81 (13/16)         | 0.71 (5/7)           |
| NPV                                      | 0.80 (24/30)        | 1.00 (42/42)         | 1.00 (51/51)         |
| Controlled attenuation parameter from TE |                     |                      |                      |
| AUROC (95% CI)                           | 0.93 (0.83–0.98)    | 0.99 (0.92–1.00)     | 0.94 (0.84–0.98)     |
| Prevalence (n)                           | 33                  | 13                   | 5                    |
| Cutoff (dB/m)                            | 209                 | 298                  | 298                  |
| Sensitivity                              | 0.94 (31/33)        | 1.00 (13/13)         | 1.00 (5/5)           |
| Specificity                              | 0.76 (19/25)        | 0.96 (43/45)         | 0.81 (43/53)         |
| PPV                                      | 0.84 (31/37)        | 0.87 (13/15)         | 0.33 (5/15)          |
| NPV                                      | 0.90 (19/21)        | 1.00 (43/43)         | 1.00 (43/43)         |

BMI, body mass index; ATI, attenuation imaging; AUROC, area under the receiver operating characteristic curve; CI, confidence interval; PPV, positive predictive value; NPV, negative predictive value; TE, transient elastography.